AR092025A1 - Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, procedimientos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos - Google Patents
Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, procedimientos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentosInfo
- Publication number
- AR092025A1 AR092025A1 ARP130102438A ARP130102438A AR092025A1 AR 092025 A1 AR092025 A1 AR 092025A1 AR P130102438 A ARP130102438 A AR P130102438A AR P130102438 A ARP130102438 A AR P130102438A AR 092025 A1 AR092025 A1 AR 092025A1
- Authority
- AR
- Argentina
- Prior art keywords
- ch2ch2
- hydrogen
- methyl
- ethyl
- trifluoromethyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 2
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 22
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- -1 methoxy, ethoxy Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- COLOHWPRNRVWPI-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound [CH2]C(F)(F)F COLOHWPRNRVWPI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 abstract 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 abstract 1
- 108010065942 Prostaglandin-F synthase Proteins 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 150000002825 nitriles Chemical group 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 abstract 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 abstract 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 abstract 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Son inhibidores de AKR1C3 que es una enzima multifuncional, útiles en especial en trastornos hemorrágicos y endometriosis. Reivindicación 1: Compuestos de la fórmula (1) en donde A es piridin-3-ilo, pirimidin-5-ilo, pirimidin-4-ilo, pirazin-2-ilo, piridazin-4-ilo, piridazin-3-ilo, opcionalmente mono- o disustituido con flúor, cloro, nitrilo, hidroxilo, carboxilo, trifluorometilo, pentafluoroetilo, metoxi, etoxi, trifluorometoxi, -OCH₂CF₃, -SO₂CH₃, -SO₂CH₂CH₃, -(C=O)CH₃, alquilo C₁₋₄, -CH₂OH, -C(CH₃)₂OH, -CONH₂, -(C=O)NHCH₃, -(C=O)NHCH₂CH₃, -(C=O)N(CH₃)₂, -SO₂NH₂, -SO₂NHCH₃, -SO₂N(CH₃)₂; R¹ es -O-CRᵃRᵇ-Y, Rᵃ y Rᵇ son, de modo independiente entre sí, hidrógeno, metilo, etilo, propilo, isopropilo, fenilo, 4-fluorofenilo, 3-fluorofenilo, 2-fluorofenilo, CH₃-O-CH₂-, -CH₂CF₃ o Rᵃ y Rᵇ son juntos -(CH₂)ₙ- con n = 2, 3, 4 ó 5, o Rᵃ y Rᵇ son juntos -CH₂-O-CH₂-, -CH₂-NH-CH₂-, -CH₂-N(CH₃)-CH₂-, -CH₂CH₂-O-CH₂CH₂-, -CH₂CH₂-NH-CH₂CH₂-, -CH₂CH₂-N(CH₃)-CH₂CH₂-; -O-CRᶜRᵈ-CRᵉRᶠ-Y, Rᶜ, Rᵈ, Rᵉ, Rᶠ son hidrógeno o Rᵉ, Rᶠ son hidrógeno y Rᶜ, Rᵈ son, de modo independiente entre sí, metilo, etilo o juntos son -(CH₂)ₙ- con n = 2, 3, 4, 5 o son juntos -CH₂-O-CH₂- o -CH₂CH₂-O-CH₂CH₂-, o Rᶜ, Rᵈ son hidrógeno y Rᵉ, Rᶠ son, de modo independiente entre sí, metilo, etilo, CF₃CH₂- o son juntos -(CH₂)ₙ- con n = 2, 3, 4, 5, -CH₂CH₂-O-CH₂CH₂-, -CH₂CH₂-NH-CH₂CH₂-, -CH₂CH₂-N(CH₃)-CH₂CH₂-, -CH₂-O-CH₂-, -CH₂-NH-CH₂-, -CH₂-N(CH₃)-CH₂-, o Rᵈ, Rᵉ, Rᶠ son hidrógeno y Rᶜ es metilo, etilo, trifluorometilo, o Rᶜ, Rᵈ, Rᶠ son hidrógeno y Rᵉ es metilo, etilo, trifluorometilo, hidroxilo, metoxi, trifluorometoxi, o Rᵈ, Rᶠ son hidrógeno y Rᶜ, Rᵉ son, de modo independiente entre sí, metilo, etilo, trifluorometilo; -O-CH₂CH₂CH₂-Y; -O-CH₂C(CH₃)₂CH₂-Y; -O-CH₂CH₂C(CH₃)₂-Y; -O-CH₂CH₂CH(CH₃)-Y; -O-CH₂-CH(OH)-CH₂-Y; -OCH₂CH₂CH₂CH₂-Y; -CH₂-Y; -CRᵍRʰ-CRⁱRʲ-Y, con Rᵍ, Rʰ, Rⁱ, Rʲ son hidrógeno, o Rᵍ, Rʰ, Rⁱ son hidrógeno y Rʲ es metilo, etilo, trifluorometilo, o Rⁱ, Rʲ son hidrógeno y Rᵍ, Rʰ son metilo o juntos son -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, o Rᵍ es metilo y Rʰ, Rⁱ, Rʲ son hidrógeno; -CH₂CH₂CH₂-Y; -CH₂CH₂C(CH₃)₂-Y; o -CH₂CH₂CH₂CH₂-Y; e Y es -CO₂H, -OH, -(C=O)NH₂, -(C=O)NH-alquilo C₁₋₄, -S(=O)CH₃; y sus sales, solvatos y solvatos de las sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012211970 | 2012-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092025A1 true AR092025A1 (es) | 2015-03-18 |
Family
ID=48748225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102438A AR092025A1 (es) | 2012-07-10 | 2013-07-10 | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, procedimientos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9512169B2 (es) |
| EP (1) | EP2872524B1 (es) |
| JP (1) | JP6196302B2 (es) |
| KR (1) | KR20150036319A (es) |
| CN (1) | CN104428309B (es) |
| AP (1) | AP2014008179A0 (es) |
| AR (1) | AR092025A1 (es) |
| AU (1) | AU2013289344A1 (es) |
| BR (1) | BR112015000443A2 (es) |
| CA (1) | CA2878485A1 (es) |
| CL (1) | CL2015000039A1 (es) |
| CO (1) | CO7160008A2 (es) |
| CR (1) | CR20150007A (es) |
| DO (1) | DOP2015000005A (es) |
| EA (1) | EA201500112A1 (es) |
| EC (1) | ECSP15000868A (es) |
| ES (1) | ES2603258T3 (es) |
| IL (1) | IL236581A0 (es) |
| MA (1) | MA37742B1 (es) |
| MX (1) | MX2015000347A (es) |
| PE (1) | PE20150353A1 (es) |
| PH (1) | PH12015500062A1 (es) |
| TN (1) | TN2015000007A1 (es) |
| TW (1) | TW201402596A (es) |
| UY (1) | UY34899A (es) |
| WO (1) | WO2014009274A1 (es) |
| ZA (1) | ZA201500920B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2958928B1 (de) | 2013-02-21 | 2018-03-28 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraen-3-carboxamide zur inhibierung von 17.beta.-hydroxysteroid dehdrogenase (akr1c3) |
| CN106687471B (zh) * | 2014-09-11 | 2018-10-30 | 拜耳医药股份公司 | 3-氮或者硫取代的雌甾-1,3,5(10),16-四烯akr1c3抑制剂 |
| US10167293B2 (en) | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
| CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
| EP3269373A1 (en) | 2016-07-11 | 2018-01-17 | Bayer Pharma Aktiengesellschaft | Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases |
| US20200085791A1 (en) | 2016-12-19 | 2020-03-19 | Bayer Pharma Aktiengesellschaft | [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones |
| US20200087284A1 (en) | 2016-12-19 | 2020-03-19 | Bayer Pharma Aktiengesellschaft | [4-(phenylsulfonyl)piperazin-1-yl](1h-1, 2, 3-triazol-4-yl)methanones |
| TW201825478A (zh) | 2016-12-19 | 2018-07-16 | 德商拜耳製藥公司 | ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮 |
| EP3421483A1 (en) | 2017-06-29 | 2019-01-02 | Bayer Pharma Aktiengesellschaft | Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3 |
| CN110693892A (zh) * | 2018-07-09 | 2020-01-17 | 深圳艾欣达伟医药科技有限公司 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
| CN110272465A (zh) * | 2019-07-15 | 2019-09-24 | 成都贝诺科成生物科技有限公司 | 阿比特龙衍生物、其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| CA2132449C (en) * | 1992-03-31 | 2002-09-10 | Susan E. Barrie | 17 - substituted steroids useful in cancer treatment |
| IL122740A (en) | 1997-01-15 | 2003-09-17 | Akzo Nobel Nv | 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them |
| EP0973790B1 (en) | 1997-04-07 | 2003-06-04 | Wyeth | Estra-5(10),7-dienes with estrogenic activity |
| WO1999046279A2 (en) | 1998-03-11 | 1999-09-16 | Endorecherche, Inc. | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
| ID28791A (id) * | 1998-08-07 | 2001-07-05 | Endorech Inc | PENGHAMBATAN DEHIDROGENASE HIDROKSISTEROID 3α TIPE 3 |
| AU2001248849A1 (en) * | 2000-04-24 | 2001-11-07 | Kyowa Hakko Kogyo Co. Ltd. | Estra-1,3,5(10)-triene derivatives |
| US7498322B2 (en) | 2004-03-12 | 2009-03-03 | Entremed, Inc. | Antiangiogenic agents |
| JP5093096B2 (ja) | 2006-03-02 | 2012-12-05 | アステラス製薬株式会社 | １７βＨＳＤｔｙｐｅ５阻害剤 |
| JP5264760B2 (ja) | 2006-11-30 | 2013-08-14 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | １７β−ＨＳＤインヒビターとしての置換エストラトリエン誘導体 |
| CA2673307A1 (en) | 2006-12-22 | 2008-07-03 | F. Hoffman-La Roche Ag | Spiro-piperidine derivatives |
| US20100190826A1 (en) | 2007-07-24 | 2010-07-29 | Akio Kakefuda | Benzimidazole derivative |
| DE102011083725A1 (de) * | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
-
2013
- 2013-07-05 US US14/414,386 patent/US9512169B2/en not_active Expired - Fee Related
- 2013-07-05 EP EP13734744.9A patent/EP2872524B1/de active Active
- 2013-07-05 AU AU2013289344A patent/AU2013289344A1/en not_active Abandoned
- 2013-07-05 JP JP2015520927A patent/JP6196302B2/ja not_active Expired - Fee Related
- 2013-07-05 MX MX2015000347A patent/MX2015000347A/es unknown
- 2013-07-05 CA CA2878485A patent/CA2878485A1/en not_active Abandoned
- 2013-07-05 EA EA201500112A patent/EA201500112A1/ru unknown
- 2013-07-05 WO PCT/EP2013/064257 patent/WO2014009274A1/de not_active Ceased
- 2013-07-05 PE PE2015000018A patent/PE20150353A1/es not_active Application Discontinuation
- 2013-07-05 ES ES13734744.9T patent/ES2603258T3/es active Active
- 2013-07-05 BR BR112015000443A patent/BR112015000443A2/pt not_active IP Right Cessation
- 2013-07-05 AP AP2014008179A patent/AP2014008179A0/xx unknown
- 2013-07-05 CN CN201380036684.4A patent/CN104428309B/zh not_active Expired - Fee Related
- 2013-07-05 KR KR20157002707A patent/KR20150036319A/ko not_active Withdrawn
- 2013-07-10 UY UY0001034899A patent/UY34899A/es not_active Application Discontinuation
- 2013-07-10 AR ARP130102438A patent/AR092025A1/es unknown
- 2013-07-10 TW TW102124795A patent/TW201402596A/zh unknown
-
2015
- 2015-01-05 IL IL236581A patent/IL236581A0/en unknown
- 2015-01-07 MA MA37742A patent/MA37742B1/fr unknown
- 2015-01-07 TN TNP2015000007A patent/TN2015000007A1/fr unknown
- 2015-01-08 CL CL2015000039A patent/CL2015000039A1/es unknown
- 2015-01-09 EC ECIEPI2015868A patent/ECSP15000868A/es unknown
- 2015-01-09 CR CR20150007A patent/CR20150007A/es unknown
- 2015-01-09 CO CO15004249A patent/CO7160008A2/es unknown
- 2015-01-09 DO DO2015000005A patent/DOP2015000005A/es unknown
- 2015-01-09 PH PH12015500062A patent/PH12015500062A1/en unknown
- 2015-02-09 ZA ZA2015/00920A patent/ZA201500920B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20150007A (es) | 2015-03-13 |
| HK1205743A1 (en) | 2015-12-24 |
| UY34899A (es) | 2014-02-28 |
| EP2872524B1 (de) | 2016-08-24 |
| KR20150036319A (ko) | 2015-04-07 |
| PH12015500062A1 (en) | 2015-03-02 |
| CL2015000039A1 (es) | 2015-03-27 |
| CO7160008A2 (es) | 2015-01-15 |
| EP2872524A1 (de) | 2015-05-20 |
| CN104428309B (zh) | 2016-09-14 |
| ES2603258T3 (es) | 2017-02-24 |
| JP2015522050A (ja) | 2015-08-03 |
| JP6196302B2 (ja) | 2017-09-13 |
| MX2015000347A (es) | 2015-04-14 |
| US9512169B2 (en) | 2016-12-06 |
| MA37742B1 (fr) | 2016-12-30 |
| AP2014008179A0 (en) | 2014-12-31 |
| EA201500112A1 (ru) | 2015-07-30 |
| WO2014009274A1 (de) | 2014-01-16 |
| TW201402596A (zh) | 2014-01-16 |
| AU2013289344A1 (en) | 2015-02-05 |
| US20150210734A1 (en) | 2015-07-30 |
| CA2878485A1 (en) | 2014-01-16 |
| PE20150353A1 (es) | 2015-03-28 |
| BR112015000443A2 (pt) | 2017-06-27 |
| ECSP15000868A (es) | 2016-01-29 |
| ZA201500920B (en) | 2017-01-25 |
| MA37742A1 (fr) | 2016-05-31 |
| TN2015000007A1 (en) | 2016-06-29 |
| DOP2015000005A (es) | 2015-02-15 |
| CN104428309A (zh) | 2015-03-18 |
| IL236581A0 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092025A1 (es) | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, procedimientos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos | |
| PH12019502355A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| EA201592198A1 (ru) | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b | |
| MX2015014033A (es) | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| MX366123B (es) | Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b. | |
| NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
| CR20160006A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
| UY32649A (es) | "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato" | |
| ZA201605979B (en) | 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
| MX2016000906A (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| UY35390A (es) | Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen | |
| UY30982A1 (es) | Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| CR20150584A (es) | Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b | |
| CU20100250A7 (es) | Compuestos pirazólicos 436 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |